Ratings Alliance Pharma plc

Equities

APH

GB0031030819

Market Closed - London S.E. Other stock markets 16:35:08 13/09/2024 BST			5-day change	1st Jan Change
43.85 ^GBX	+3.42%		+13.60%	+8.27%

09-02	Alliance Pharma plc Announces Termination of Jeyan Heper as Director	CI
08-12	EXECUTIVE CHANGES: New chief executives at Cornish Metals and ValiRx	AN

Highlights: Alliance Pharma plc

The company's share price in relation to its net book value makes it look relatively cheap.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses: Alliance Pharma plc

The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings Chart: Alliance Pharma plc

Source: Surperformance

ESG chart: Alliance Pharma plc

Source: Refinitiv

Sector Comparison:

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Fundamentals	Composite Valuation	Composite Momentum	Capi. ($)
	ALLIANCE PHARMA PLC				312M
	SUN PHARMACEUTICAL INDUSTRIES LTD.				53.02B
	OTSUKA HOLDINGS CO., LTD.				30.94B
	SANDOZ GROUP AG				17.85B
	CIPLA LIMITED				15.98B
	ZYDUS LIFESCIENCES LIMITED				13.42B
	ONO PHARMACEUTICAL CO., LTD.				6.38B
	GLENMARK PHARMACEUTICALS LIMITED				5.9B
	Average				17.98B
	Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

C+

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes